PEAK6 Investments’s Royalty Pharma RPRX Stock Holding History

PEAK6 Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,238	Closed	-$157K	–	4865
2022 Q4	$167K	Buy	+4,238	New	+$177K	﹤0.01%	3392

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PEAK6 Investments's RPRX Position: Q1 2023 in Review

PEAK6 Investments sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 4,238 shares — an estimated $157K sold.

PEAK6 Investments first reported a position in RPRX in Q4 2022 and held it in 1 quarter. The position peaked at $167K in Q4 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

PEAK6 Investments reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
PEAK6 Investments sold 4,238 Royalty Pharma shares in Q1 2023, an estimated $157K.
PEAK6 Investments first reported a position in Royalty Pharma in Q4 2022 and held it in 1 quarter.
PEAK6 Investments's Royalty Pharma position peaked at $167K in Q4 2022.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on PEAK6 Investments's 13F filing for Q1 2023, filed 12 May 2023.